Healthcare provider profile · identity verified

Laura Trueman, MD

Internal Medicine · CAMBRIDGE, MA · NPI 1174987333

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	612	170
Amlodipine Besylate	Amlodipine Besylate	342	98
Fluticasone Propionate	Fluticasone Propionate	266	71
Famotidine	Famotidine	211	55
Albuterol Sulfate Hfa	Albuterol Sulfate	198	33
Losartan Potassium	Losartan Potassium	193	51
Lisinopril	Lisinopril	185	53
Metoprolol Succinate	Metoprolol Succinate	184	48
Omeprazole	Omeprazole	182	58
Trulicity	Dulaglutide	180	36
Diclofenac Sodium	Diclofenac Sodium	163	35
Metformin Hcl	Metformin Hcl	160	42
Jardiance	Empagliflozin	153	44
Triamcinolone Acetonide	Triamcinolone Acetonide	134	38
Simvastatin	Simvastatin	128	31
Gabapentin	Gabapentin	112	31
Metformin Hcl Er	Metformin Hcl	112	33
Levothyroxine Sodium	Levothyroxine Sodium	90	25
Pantoprazole Sodium	Pantoprazole Sodium	89	19
Tamsulosin Hcl	Tamsulosin Hcl	89	20
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	71	30
Sertraline Hcl	Sertraline Hcl	71	20
Ammonium Lactate	Ammonium Lactate	69	14
Rosuvastatin Calcium	Rosuvastatin Calcium	66	28
Ibuprofen	Ibuprofen	65	20
Pravastatin Sodium	Pravastatin Sodium	65	19
Trazodone Hcl	Trazodone Hcl	64	17
Oxycodone Hcl	Oxycodone Hcl	63	suppressed
Ventolin Hfa	Albuterol Sulfate	62	16
Chlorthalidone	Chlorthalidone	61	21
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	59	15
Alendronate Sodium	Alendronate Sodium	58	14
Eliquis	Apixaban	56	13
Spironolactone	Spironolactone	56	16
Lidocaine	Lidocaine	53	16
Hydrochlorothiazide	Hydrochlorothiazide	52	17
Lactulose	Lactulose	48	suppressed
Mirtazapine	Mirtazapine	47	14
Furosemide	Furosemide	46	11
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	45	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	45	12
Allopurinol	Allopurinol	42	11
Nortriptyline Hcl	Nortriptyline Hcl	42	suppressed
Naproxen	Naproxen	41	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	40	11
Clobetasol Propionate	Clobetasol Propionate	39	suppressed
Memantine Hcl	Memantine Hcl	39	suppressed
Single Use Swab	Alcohol Antiseptic Pads	35	13
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	33	suppressed
Dulera	Mometasone/Formoterol	32	suppressed
Nifedipine Er	Nifedipine	31	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	30	suppressed
Glipizide Er	Glipizide	30	11
Meclizine Hcl	Meclizine Hcl	30	suppressed
Valsartan	Valsartan	30	suppressed
Nystatin	Nystatin	28	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	24	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	24	suppressed
Donepezil Hcl	Donepezil Hcl	23	suppressed
Glipizide	Glipizide	23	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	23	suppressed
Tizanidine Hcl	Tizanidine Hcl	22	suppressed
Atenolol	Atenolol	21	suppressed
Ezetimibe	Ezetimibe	21	suppressed
Hydrocortisone	Hydrocortisone	21	suppressed
Loperamide	Loperamide Hcl	21	12
Prednisone	Prednisone	21	12
Advair Hfa	Fluticasone Propion/Salmeterol	20	suppressed
Betamethasone Valerate	Betamethasone Valerate	20	suppressed
Torsemide	Torsemide	19	suppressed
Citalopram Hbr	Citalopram Hydrobromide	18	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Incruse Ellipta	Umeclidinium Bromide	17	suppressed
Warfarin Sodium	Warfarin Sodium	17	suppressed
Duloxetine Hcl	Duloxetine Hcl	16	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	16	suppressed
Farxiga	Dapagliflozin Propanediol	16	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	16	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Alcohol Pads	Alcohol Antiseptic Pads	14	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	14	suppressed
Easy Touch Alcohol Prep Pads	Alcohol Antiseptic Pads	14	suppressed
Humalog Kwikpen U-100	Insulin Lispro	14	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	14	suppressed
Peg-3350 And Electrolytes	Peg3350/Sod Sulf,bicarb,cl/Kcl	14	13
Procto-Med Hc	Hydrocortisone	14	suppressed
Tramadol Hcl	Tramadol Hcl	14	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	14	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	13	suppressed
Carvedilol	Carvedilol	13	suppressed
Entecavir	Entecavir	13	suppressed
Montelukast Sodium	Montelukast Sodium	13	suppressed
Potassium Chloride	Potassium Chloride	13	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	13	suppressed
Arnuity Ellipta	Fluticasone Furoate	12	suppressed
Breo Ellipta	Fluticasone/Vilanterol	12	suppressed
Clopidogrel	Clopidogrel Bisulfate	12	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	12	suppressed
Finasteride	Finasteride	12	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	12	suppressed
Nystop	Nystatin	12	suppressed
Ropinirole Hcl	Ropinirole Hcl	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Clonazepam	Clonazepam	11	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed
Fluconazole	Fluconazole	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	11	suppressed
Propranolol Hcl Er	Propranolol Hcl	11	suppressed
Qvar Redihaler	Beclomethasone Dipropionate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error